BBOT — BridgeBio Oncology Therapeutics, Inc. · rev $7.5M

BridgeBio Oncology Therapeutics, Inc. (BBOT) is a biotechnology company listed on NASDAQ.

Latest reported BBOT revenue for 2026-06-30 was $7.5M. Net income was -$98.6M. Revenue was up 90.0% from 2026-03-31 to 2026-06-30. BBOT currently screens at market cap $610.4M.

Use this BBOT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BBOT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BBOT SEC filings page. Lician reads the product cache first so this HTML stays unique to BridgeBio Oncology Therapeutics, Inc. even when a live quote feed is slow.

BridgeBio Oncology Therapeutics, Inc. latest statements (Q3 2025)

Latest cached year on this hub. Full BBOT income, balance, and cash tables.

  • Revenue$3.4M
  • Net Income-$44.8M
  • Total Assets$194.4M
  • Total Debt$0
  • Free Cash Flow-$72.2M

BBOT recent filings